VivoSeq
Other

Relapse

0

Pipeline Programs↗

10

Active Trials↗

7

Companies Involved↗

Relapse is an early-stage landscape with 0 programs across 7 companies. The most active players are Kiadis Pharma, Lykos Therapeutics, Luye Pharma Group Ltd..

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

68/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kiadis Pharma

0 programs

PreclinicalL

Lykos Therapeutics

0 programs

PreclinicalLuye Pharma Group Ltd. logo

Luye Pharma Group Ltd.

0 programs

PreclinicalP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

0 programs

PreclinicalKyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.

0 programs

PreclinicalGilead logo

Gilead

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

50

clinical trials

Completed23 · 46%
Terminated7 · 14%
Unknown status6 · 12%
Withdrawn4 · 8%
Recruiting4 · 8%
Active, not recruiting4 · 8%
Other2 · 4%

Clinical Trials

Trial Activity

50 trials

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Recruiting·Luye Pharma Group Ltd. logoLuye Pharma Group Ltd.·Phase 3·NCT06496048·180 enrolled
COLLISION RELAPSE Trial
Recruiting·AAmsterdam UMC, location VUmc·Phase 3·NCT05861505·360 enrolled
Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse
Recruiting·YYale University·Phase 2·NCT06609369·114 enrolled
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
Recruiting·AAustralasian Leukaemia and Lymphoma Group·Phase 2·NCT06287398·39 enrolled
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Active, not recruiting·—·Phase 1·NCT02787369·3 enrolled
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
Active, not recruiting·—·Phase 1·NCT02379520·32 enrolled
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
Active, not recruiting·—·Phase 2·NCT04624633·29 enrolled
Venetoclax in Patients With MDS or AML in Relapse After AHSCT
Active, not recruiting·GGroupe Francophone des Myelodysplasies·Phase 1/2·NCT05226455·55 enrolled
Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP
Not yet recruiting·PPeking University People's Hospital·Phase 2·NCT07057778·120 enrolled
Effectiveness, Patient Acceptance, and Cost Estimation of 3D-printed Retainer Compared to Hawley Retainer in Expansion Case: a Randomized Controlled Trial
Not yet recruiting·NNational University of Malaysia·Preclinical·NCT07659041·28 enrolled
Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial
Completed·LLykos Therapeutics·Phase 2·NCT01458327·3 enrolled
Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
Completed·NNorthside Hospital, Inc.·Phase 2·NCT02771197·20 enrolled
Galantamine and CBT4CBT Pilot to Prevent Relapse.
Completed·YYale University·Phase 1·NCT03547622·6 enrolled
Modafinil, Sleep Architecture and Cocaine Relapse
Completed·YYale University·Phase 2·NCT01137396·114 enrolled
Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin
Completed·—·Phase 4·NCT00207402·34 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)